PCMTD1 as A Potential Drug Target and Biomarker (G115294)

Target Name: PCMTD1

NCBI ID: G115294

PCMTD1

Other Name(s): Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1, transcript variant 2 | PCMD1_HUMAN | Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 (isoform 1) | PCMTD1 variant 2 | Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 (isoform 2) | FLJ10883 | PCMTD1 variant 1 | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 | Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1, transcript variant 1 | Protein-L-isoaspartate O-methyltransferase domain-containing protein 1

PCMTD1 as A Potential Drug Target and Biomarker

Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 (PCMTD1) is a protein that is expressed in various tissues and cells of the body. It plays a crucial role in the regulation of cellular processes, including cell growth, differentiation, and metabolism. PCMTD1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Related PCMTD1 Expression

PCMTD1 is involved in the regulation of key cellular processes that are affected in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It has been shown to be expressed in various tissues and cells of the body, including brain, spinal cord, pancreas, muscle, liver, and blood cells. It is also expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

In neurodegenerative diseases, PCMTD1 has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the modulation of cellular signaling pathways. It has been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In autoimmune disorders, PCMTD1 has been shown to be involved in the regulation of immune cell function and the development of autoimmune diseases. It has been shown to play a role in the development of rheumatoid arthritis, lupus, and other autoimmune disorders.

Potential Drug Target

PCMTD1 has been identified as a potential drug target due to its involvement in various cellular processes that are affected in many diseases. Its ability to modulate cellular signaling pathways and its involvement in the regulation of key cellular processes make it an attractive target for drug development.

One of the main advantages of PCMTD1 as a drug target is its druggable nature. The PCMTD1 protein is located within a transmembrane domain and has multiple potential druggable sites. Studies have shown that several small molecules have been shown to be effective in blocking PCMTD1, including inhibitors of tyrosine kinase activity, inhibitors of protein-protein interactions, and inhibitors of DNA binding.

Another advantage of PCMTD1 as a drug target is its role in the regulation of cellular signaling pathways. PCMTD1 has been shown to play a role in the regulation of multiple cellular signaling pathways, including T cell signaling, neurotransmitter synthesis and release, and intracellular signaling pathways. Drugs that target PCMTD1 have been shown to be effective in modulating cellular signaling pathways and have been shown to be effective in treating various diseases.

Conclusion

In conclusion, PCMTD1 is a protein that has been shown to be involved in the regulation of various cellular processes that are affected in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to modulate cellular signaling pathways and its involvement in key cellular processes make it an attractive target for drug development. Further research is needed to fully understand the role of PCMTD1 as a drug target and its potential as a biomarker for various diseases.

Protein Name: Protein-L-isoaspartate (D-aspartate) O-methyltransferase Domain Containing 1

Functions: Substrate recognition component of an ECS (Elongin BC-CUL5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:35486881). Specifically binds to the methyltransferase cofactor S-adenosylmethionine (AdoMet) via the N-terminal AdoMet binding motif, but does not display methyltransferase activity (PubMed:35486881). May provide an alternate maintenance pathway for modified proteins by acting as a damage-specific E3 ubiquitin ligase adaptor protein (PubMed:35486881)

The "PCMTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCMTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets